Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Colorcon
Express Scripts
Medtronic

Last Updated: September 27, 2022

Investigational Drug Information for MEK162


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the drug development status for MEK162?

MEK162 is an investigational drug.

There have been 67 clinical trials for MEK162. The most recent clinical trial was a Phase 3 trial, which was initiated on June 28th 2013.

The most common disease conditions in clinical trials are Melanoma, Neoplasms, and Colorectal Neoplasms. The leading clinical trial sponsors are Array BioPharma, Pfizer, and National Cancer Institute (NCI).

There are five hundred and seven US patents protecting this investigational drug and four international patents.

Recent Clinical Trials for MEK162
TitleSponsorPhase
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors.PfizerPhase 1
Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung CancerPierre Fabre MedicamentPhase 2
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast CancerNational Cancer Institute (NCI)Phase 1

See all MEK162 clinical trials

Clinical Trial Summary for MEK162

Top disease conditions for MEK162
Top clinical trial sponsors for MEK162

See all MEK162 clinical trials

US Patents for MEK162

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
MEK162 See Plans and Pricing Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) See Plans and Pricing
MEK162 See Plans and Pricing Compounds and compositions as protein kinase inhibitors Array BioPharma Inc. (Boulder, CO) See Plans and Pricing
MEK162 See Plans and Pricing Anti-CS1 antibodies and antibody drug conjugates AbbVie Biotherapeutics Inc. (Redwood City, CA) See Plans and Pricing
MEK162 See Plans and Pricing .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) See Plans and Pricing
MEK162 See Plans and Pricing Compounds for treatment of cancer UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (Knoxville, TN) See Plans and Pricing
MEK162 See Plans and Pricing Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors Array BioPharma Inc. (Boulder, CO) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for MEK162

Drugname Country Document Number Estimated Expiration Related US Patent
MEK162 Australia AU2015244171 2034-04-11 See Plans and Pricing
MEK162 Australia AU2015244179 2034-04-11 See Plans and Pricing
MEK162 Canada CA2945128 2034-04-11 See Plans and Pricing
MEK162 Canada CA2945129 2034-04-11 See Plans and Pricing
MEK162 China CN106414451 2034-04-11 See Plans and Pricing
MEK162 China CN106459063 2034-04-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
Merck
Colorcon
Express Scripts
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.